May 16 (Reuters) - British drugmaker GSK said on Thursday it plans to sell about 385 million shares, representing its entire shareholding, in spun-off consumer healthcare business Haleon. (Reporting by Anchal Rana in Bengaluru; Editing by Shilpi Majumdar)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,629 GBX | -0.67% | -7.78% | +12.33% |
Jun. 07 | GSK says FDA Approves Expanded Age Indication For Arexvy, RSV Vaccine For Adults Aged 50-59 At Increased Risk | RE |
Jun. 07 | GSK -CLINICAL DEVELOPMENT PROGRAMME CONTINUES TO EVALUATE SAFETY… | RE |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
1,629 GBX | -0.67% | -7.78% | 85.51B | ||
330.3 GBX | -0.30% | +1.60% | 38.68B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.33% | 85.51B | |
+45.82% | 754B | |
+40.95% | 630B | |
-6.16% | 352B | |
+19.86% | 331B | |
+9.32% | 298B | |
+18.45% | 250B | |
+11.88% | 217B | |
-0.78% | 216B | |
+5.90% | 164B |
- Stock Market
- Equities
- GSK Stock
- News GSK plc
- GSK intends to sell its entire stake in Haleon